Journal
NEUROMOLECULAR MEDICINE
Volume 13, Issue 4, Pages 217-222Publisher
HUMANA PRESS INC
DOI: 10.1007/s12017-011-8154-x
Keywords
BDNF; Alzheimer's disease; Mild cognitive impairment; Biomarker; Physiopathology
Categories
Funding
- Coordenacao de Aperfeicoamento Pessoal do Ensino Superior (CAPES, Brazil)
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)
- Fundacao de Amparo a Pesquisa de Minas Gerais (Fapemig, Brazil)
- Fundacao de Amparo a Pesquisa de Sao Paulo (FAPESP, Brazil)
- Associacao Beneficente Alzira Denise Hertzog da Silva (ABADHS)
Ask authors/readers for more resources
Brain-derived neurotrophic factor (BDNF) is the most widely distributed neurotrophin in the central nervous system where it plays several pivotal roles in synaptic plasticity and neuronal survival. As a consequence, BDNF became a key target in the physiopathology of several neurological and psychiatric diseases. Recent studies have reported altered levels of BDNF in the circulation, i.e. serum or plasma, of patients with Alzheimer's disease (AD), and low BDNF levels in the CSF as predictor of future cognitive decline in healthy older subjects. Altered BDNF circulating levels have also been reported in other neurodegenerative and psychiatric disorders, hampering its use as a specific biomarker for AD. Therefore, BDNF seems to be an unspecific biomarker of neuropsychiatric disorders marked by neurodegenerative changes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available